Abstract:Background: Furosemide is a commonly used loop diuretic in critical care. However, its effect on the progression of oliguric acute kidney injury across different central venous pressure (CVP) remains unknown. This study therefore aims to investigate the association between furosemide(6-12h ) (defined as the use of furosemide within 6 h after the diagnosis of AKI according to the urine output [UO] criteria set by the Kidney Disease: Improving Global Outcomes [KDIGO] guidelines) and the progression of AKI across different CVP6-12h (defined as CVP within 6 h after the diagnosis of AKI by the KDIGO UO criteria) levels. Methods: Patients involved in this study were identified from the Medical Information Mart for Intensive Care IV database with the following criteria: (i) adults with UO < 0.5 mL/kg per hour for the first 6 h upon admission to the intensive care unit (ICU) (meeting stage 1 AKI by UO) and (ii) CVP6-12h ranging from 0 to 30 mm Hg. From there on, the target primary outcome would be progression to stage 3 AKI by UO among these chosen patients. The secondary outcome was 28-d mortality since ICU admission. The risks of severe-stage AKI progression and 28-d mortality were respectively examined against furosemide(6-12h ) (vs. without furosemide6-12h) within the full cohort and across different subgroups of CV6-12h , using multivariate adjusted logistic regression and inverse probability treatment weighting (IPTW). Sensitivity analyses were performed to assess the robustness of our findings. Results: One thousand one hundred eighty patients were ultimately selected for this study, of whom 643 (54.5%) progressed to stage 3 AKI from stage 1 based on the UO criteria by KDIGO. Multivariate analysis showed that furosemide(6-12h ) is significantly associated with this severe-stage progression within the full cohort (odds ratio [OR] was 0.62 at 95% confidence interval [CI] of 0.43-0.90, P = 0.011). After dividing the patients into CVP6-12h subgroups according to their CVP during the early phases, lower risk of AKI progression was observed only in furosemide(6-12h ) application at CVP6-12h of > 12 mm Hg (adjusted OR was 0.40 at 95% CI of 0.25-0.65, P < 0.001), as confirmed by the IPTW analysis (OR was 0.47 at 95% CI of 0.29-0.76, P = 0.002). The robustness of these findings was confirmed by sensitivity analyses. In addition, for patients with CVP6-12h > 12 mm Hg, furosemide(6-12h ) is also significantly associated with lower risk of 28-d mortality (adjusted OR was 0.47 at 95% CI of 0.25-0.92, P = 0.026) in the multivariate logistic regression analysis, and there was a similar trend in the IPTW analysis (adjusted OR was 0.55 at 95% CI of 0.28-1.10, P = 0.092). Conclusions: Among the identified early-stage AKI patients in critical care, the use of furosemide was associated only with lower risk of oliguric AKI progression and 28-d mortality within the high CVP group. These findings suggest the potential of CVP as a guidance or reference point in the usage of furosemide among early-stage oliguric AKI patients in the ICU.

New Insights Into Diuretic Use to Treat Congestion in the ICU: Beyond Furosemide

Management of loop diuretic resistance in the intensive care unit

Contemporary Decongestive Strategies in Acute Heart Failure

The furosemide stress test: current use and future potential

The utility of urine sodium–guided diuresis during acute decompensated heart failure

Decongestion (instead of ultrafiltration?)

Decongestion in Acute Heart Failure—Time to Rethink and Standardize Current Clinical Practice?

Proximal versus distal diuretics in congestive heart failure

Efficacy of acetazolamide as adjunct therapy in improving fluid management in patients with acute congestive heart failure: a systematic review and meta-analysis of randomized controlled trials

Combination of diuretics to overcome diuretic resistance in acute heart failure: systematic review and updated network meta-analysis

The Role of Subcutaneous Furosemide in Heart Failure Management: A Systematic Review

Treatment strategies for diuretic resistance in patients with heart failure

The effects of early-phase furosemide use on the progression of oliguric acute kidney injury across different central venous pressure: a retrospective analysis

The management of acute heart failure and diuretic therapy

Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intra-patient Comparison of Three Diuretic Regimens (DEA-HF)

From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion

Combination Diuretic Therapy to Counter Renal Sodium Avidity in Acute Heart Failure: Trials and Tribulations

Extracorporeal veno-venous ultrafiltration in congestive heart failure: What’s the state of the art? A mini-review

Decongestion in acute heart failure: Is it time to change diuretic‐centred paradigm?

Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure

The Changing Role of Loop Diuretics in Heart Failure Management across the Last Century